Abbott finishes strongly before spin-off
pharmafile | January 25, 2013 | News story | Sales and Marketing | AbbVie, Abbott, Q4 2012
Abbott has presented its full-year results for 2012 – the last in which many of its products will appear, following the AbbVie split-off earlier this month.
While sales for the combined entity for the year were $39.9 billion, up just 2.6%, net profit rose 10.7% to $8.1 billion after $573 million of restructuring charges and $485 million of ‘separation’ cost was taken out.
As expected, Humira – now an AbbVie drug – was again the driving force behind the company, with sales of $9.3 billion over the year, a 16.8% improvement on 2011.
The rheumatoid arthritis brand has eight indications in Europe and seven in the US but its US patent expires in December 2016.
Total sales of proprietary drugs – the bit of Abbott now under the AbbVie banner – were $18 billion, up 5.5% year on year.
That leaves Abbott on its own – with operations including branded generic pharma, devices, diagnostics and nutritionals – with a turnover of $21.9 billion.
“Abbott’s mix of diversified healthcare businesses and pipeline is favourably aligned with key healthcare and emerging market trends and well-positioned to deliver top-tier growth in 2013,” insisted Abbott chief executive Miles D. White.
AbbVie will market brands such as anti-HIV treatment Kaletra and prostate cancer drug Lupron.
Kaletra’s sales for the year were just over $1 billion, down 13.4% year on year, while Lupron’s fell 1.2% to $800 million.
The Trilipix/Tricor lipids franchise dropped 17.4% to $1.4 billion.
Adam Hill
Related Content
Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …
Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …
